Pharmacoenhancer - Cytochrome P450 Inhibitors

Pharmacoenhancer cytochrome P450 inhibitors, also known as pharmacokinetic enhancers or "boosting" agents, are drugs specifically administered to inhibit hepatic and intestinal cytochrome P450 enzymes—predominantly the CYP3A subfamily Because of their potent CYP inhibition, they also carry a high potential for clinically significant drug-drug interactions with other concomitantly administered substrates

Pharmacoenhancer cytochrome P450 inhibitors, also known as pharmacokinetic enhancers or "boosting" agents, are drugs specifically administered to inhibit hepatic and intestinal cytochrome P450 enzymes—predominantly the CYP3A subfamily

By intentionally suppressing the enzymatic degradation and first-pass metabolism of coadministered therapeutic compounds, these agents increase systemic drug exposure, prolong therapeutic half-life, and allow for lower or less frequent dosing

By intentionally suppressing the enzymatic degradation and first-pass metabolism of coadministered therapeutic compounds, these agents increase systemic drug exposure, prolong therapeutic half-life, and allow for lower or less frequent dosing

By intentionally suppressing the enzymatic degradation and first-pass metabolism of coadministered therapeutic compounds, these agents increase systemic drug exposure, prolong therapeutic half-life, and allow for lower or less frequent dosing

Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2

Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2

Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2 Because of their potent CYP inhibition, they also carry a high potential for clinically significant drug-drug interactions with other concomitantly administered substrates

Represented primarily by agents such as ritonavir and cobicistat, this functional class is most extensively utilized in combination antiretroviral therapies for human immunodeficiency virus (HIV) and in antiviral regimens for hepatitis C virus (HCV) and SARS-CoV-2